Clinical Trial

Evaluation of Side Effects of Mitotane

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
Mitotane is standard therapy in the treatment of adrenocortical carcinoma. However, many adverse effects are not well documented. Therefore, we are aiming at collecting data about adverse effects in patients treated with mitotane
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2007-12-04; most recent amendment 2026-05-01.
Status change: Recruiting → Active, Not Recruiting 2024-04-23
Status change: Not Yet Recruiting → Recruiting 2010-01-12
Trial Details
NCT Number NCT00568139
Lead Sponsor University of Wuerzburg
Conditions Adrenocortical Carcinoma
Enrollment 400 participants
Start Date 2008-01
Primary Completion 2027-12 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-07